NCT05064358
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05064358
Title Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14)
Acronym DREAMM 14
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUS | ARG

Facility Status City State Zip Country Details
GSK Investigational Site West Palm Beach Florida 33401 United States Details
GSK Investigational Site Kansas City Missouri 64114 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Chattanooga Tennessee 37404 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Houston Texas 77090 United States Details
GSK Investigational Site Buenos Aires C1181ACH Argentina Details
GSK Investigational Site Capital Federal C1426ANZ Argentina Details
GSK Investigational Site Ciudad Autonoma de Buenos Aire 1414 Argentina Details
GSK Investigational Site Pilar B1629AHJ Argentina Details
GSK Investigational Site Rosario S2002 Argentina Details
GSK Investigational Site Liverpool New South Wales 2170 Australia Details
GSK Investigational Site Newcastle New South Wales 2298 Australia Details
GSK Investigational Site Woodville South Australia 5011 Australia Details
GSK Investigational Site East Melbourne Victoria 3002 Australia Details
GSK Investigational Site Joinville 89201-260 Brazil Details
GSK Investigational Site Porto Alegre 90850-170 Brazil Details
GSK Investigational Site Rio de Janeiro 22271-110 Brazil Details
GSK Investigational Site Salvador 41253-190 Brazil Details
GSK Investigational Site São Paulo 01236-030 Brazil Details
GSK Investigational Site São Paulo 04537-080 Brazil Details
GSK Investigational Site Oshawa Ontario L1G 2B9 Canada Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
GSK Investigational Site Montreal Quebec H4J 1C5 Canada Details
GSK Investigational Site Avignon 84902 France Details
GSK Investigational Site Nice 06189 France Details
GSK Investigational Site Orléans 45100 France Details
GSK Investigational Site Cottbus 03048 Germany Details
GSK Investigational Site Dresden 01307 Germany Details
GSK Investigational Site Greifswald 17475 Germany Details
GSK Investigational Site Hamburg 22763 Germany Details
GSK Investigational Site Athens 106 76 Greece Details
GSK Investigational Site Athens 11528 Greece Details
GSK Investigational Site Athens 12462 Greece Details
GSK Investigational Site Rio Patras 26504 Greece Details
GSK Investigational Site Ahmedabad 380009 India Details
GSK Investigational Site Apex Wellness Hospital 422005 India Details
GSK Investigational Site Hyderabad 500033 India Details
GSK Investigational Site Kolkata 700014 India Details
GSK Investigational Site Kolkata 700156 India Details
GSK Investigational Site M S R Nagar Msrit Post 560054 India Details
GSK Investigational Site Pune 411004 India Details
GSK Investigational Site Sushrut Hospital and Research 400071 India Details
GSK Investigational Site Dublin 8 Ireland Details
GSK Investigational Site Dublin D09 V2N0 Ireland Details
GSK Investigational Site Alessandria 15121 Italy Details
GSK Investigational Site Ascoli Piceno 63100 Italy Details
GSK Investigational Site Cagliari 09121 Italy Details
GSK Investigational Site Ferrara 44124 Italy Details
GSK Investigational Site Genova 16132 Italy Details
GSK Investigational Site Meldola FC 47014 Italy Details
GSK Investigational Site Reggio Emilia 42123 Italy Details
GSK Investigational Site Rimini 47900 Italy Details
GSK Investigational Site Mexico City 03100 Mexico Details
GSK Investigational Site Mexico City 03720 Mexico Details
GSK Investigational Site Bydgoszcz 85-168 Poland Details
GSK Investigational Site Gdansk 80-214 Poland Details
GSK Investigational Site Katowice 40-519 Poland Details
GSK Investigational Site Lublin 20-081 Poland Details
GSK Investigational Site Poznan 60-569 Poland Details
GSK Investigational Site Torun 87-100 Poland Details
GSK Investigational Site Warsaw 02-781 Poland Details
GSK Investigational Site Wałbrzych 58-309 Poland Details
GSK Investigational Site Wroclaw 50-367 Poland Details
GSK Investigational Site Hwasun 58128 South Korea Details
GSK Investigational Site Pusan 49241 South Korea Details
GSK Investigational Site Seoul 03080 South Korea Details
GSK Investigational Site Seoul 06591 South Korea Details
GSK Investigational Site Albacete 02006 Spain Details
GSK Investigational Site Barcelona 08026 Spain Details
GSK Investigational Site Córdoba 140044 Spain Details
GSK Investigational Site Girona 17007 Spain Details
GSK Investigational Site Oviedo 33011 Spain Details
GSK Investigational Site Terrassa - Barcelona 08221 Spain Details
GSK Investigational Site Valencia 46010 Spain Details
GSK Investigational Site Bern 3010 Switzerland Details
GSK Investigational Site Taichung 404 Taiwan Details
GSK Investigational Site Taichung 40705 Taiwan Details
GSK Investigational Site Tainan 704 Taiwan Details
GSK Investigational Site Taipei 100 Taiwan Details
GSK Investigational Site Taipei 112 Taiwan Details
GSK Investigational Site Bangkok 10210 Thailand Details
GSK Investigational Site Bangkok 10330 Thailand Details
GSK Investigational Site Chiang Mai 50200 Thailand Details
GSK Investigational Site Khon Kaen 40002 Thailand Details
GSK Investigational Site Leicester LE1 5WW United Kingdom Details
GSK Investigational Site London W12 0HS United Kingdom Details
GSK Investigational Site Stoke-on-Trent ST4 6QG United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field